Mogamulizumab: 2 birds, 1 stone

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Mycosis fungoides (MF) and Sézary syndrome (SS) are advanced cutaneous T-cell lymphomas.
• Treatment options for heavily pretreated patients with MF and SS are limited.

Purpose of the Study:

• To evaluate the safety and efficacy of mogamulizumab in patients with MF and SS.
• To assess the clinical activity and response duration of mogamulizumab in this patient population.

Main Methods:

• A clinical trial involving heavily pretreated patients with MF and SS.
• Administration of mogamulizumab, a humanized monoclonal antibody targeting chemokine receptor CCR4.

Main Results:

• Mogamulizumab was well tolerated in the study population.
• Significant clinical activity was observed, with an overall response rate of 36.8%.
• The median duration of response was 10.4 months.

Conclusions:

• Mogamulizumab demonstrates favorable tolerability and significant clinical activity in heavily pretreated patients with MF and SS.
• This antibody represents a promising therapeutic option for advanced cutaneous T-cell lymphomas.